0000899243-22-026190.txt : 20220715 0000899243-22-026190.hdr.sgml : 20220715 20220715204609 ACCESSION NUMBER: 0000899243-22-026190 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220713 FILED AS OF DATE: 20220715 DATE AS OF CHANGE: 20220715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jones Anne CENTRAL INDEX KEY: 0001869584 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38914 FILM NUMBER: 221087977 MAIL ADDRESS: STREET 1: C/O CELULARITY INC. STREET 2: 170 PARK AVENUE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celularity Inc CENTRAL INDEX KEY: 0001752828 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831702591 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (908) 768-2170 MAIL ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: GX Acquisition Corp. DATE OF NAME CHANGE: 20180912 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-13 0 0001752828 Celularity Inc CELU 0001869584 Jones Anne C/O CELULARITY INC. 170 PARK AVENUE FLORHAM PARK NJ 07932 0 1 0 0 Chief Business Officer Class A Common Stock 2022-07-13 4 A 0 11483 0.00 A 27888 D Stock Option (Right to Buy) 10.16 2022-07-13 4 A 0 33670 0.00 A 2032-07-13 Class A Common Stock 33670 33670 D These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is subject to time-based vesting over a four-year period, with 25% vesting on the one-year anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date. This option was granted under the 2021 Plan and shall vest and become exercisable over a four-year period, with 25% of the option vesting on April 13, 2023, and the remainder vesting in equal monthly installments thereafter so that vested in full on April 13, 2026, and subject to the Reporting Person's continuous service on each vesting date. /s/ Keary Dunn, Attorney-in-Fact 2022-07-15